JP7022081B2 - 抗凝固因子ｘｉ抗体 - Google Patents

抗凝固因子ｘｉ抗体 Download PDF

Info

Publication number
JP7022081B2
JP7022081B2 JP2018565042A JP2018565042A JP7022081B2 JP 7022081 B2 JP7022081 B2 JP 7022081B2 JP 2018565042 A JP2018565042 A JP 2018565042A JP 2018565042 A JP2018565042 A JP 2018565042A JP 7022081 B2 JP7022081 B2 JP 7022081B2
Authority
JP
Japan
Prior art keywords
amino acid
antibody
seq
acid sequence
fxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018565042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521978A (ja
Inventor
チェン，ジュー
エルスワース，ケネス、ピー
ミリガン，ジェームズ
オールドハム，エリザベス
シーファー，ディートマール
ガンティ，ヴィシュナビ
タブリージファード，モハマド
プリンツ，ビアンカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2019521978A publication Critical patent/JP2019521978A/ja
Priority to JP2021053470A priority Critical patent/JP7277500B2/ja
Application granted granted Critical
Publication of JP7022081B2 publication Critical patent/JP7022081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
JP2018565042A 2016-06-14 2017-06-12 抗凝固因子ｘｉ抗体 Active JP7022081B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021053470A JP7277500B2 (ja) 2016-06-14 2021-03-26 抗凝固因子ｘｉ抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14
US62/349,888 2016-06-14
PCT/US2017/036940 WO2017218371A1 (en) 2016-06-14 2017-06-12 Anti-coagulation factor xi antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021053470A Division JP7277500B2 (ja) 2016-06-14 2021-03-26 抗凝固因子ｘｉ抗体

Publications (2)

Publication Number Publication Date
JP2019521978A JP2019521978A (ja) 2019-08-08
JP7022081B2 true JP7022081B2 (ja) 2022-02-17

Family

ID=59078269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018565042A Active JP7022081B2 (ja) 2016-06-14 2017-06-12 抗凝固因子ｘｉ抗体
JP2021053470A Active JP7277500B2 (ja) 2016-06-14 2021-03-26 抗凝固因子ｘｉ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021053470A Active JP7277500B2 (ja) 2016-06-14 2021-03-26 抗凝固因子ｘｉ抗体

Country Status (29)

Country Link
US (6) US10676536B2 (enExample)
EP (1) EP3469002A1 (enExample)
JP (2) JP7022081B2 (enExample)
KR (2) KR102379580B1 (enExample)
CN (2) CN116425879A (enExample)
AR (1) AR108717A1 (enExample)
AU (3) AU2017286432B2 (enExample)
BR (1) BR112018075858A2 (enExample)
CA (2) CA3025869C (enExample)
CL (2) CL2018003565A1 (enExample)
CO (1) CO2018013434A2 (enExample)
CR (1) CR20180583A (enExample)
DO (1) DOP2018000284A (enExample)
EA (1) EA201892716A1 (enExample)
EC (1) ECSP18091593A (enExample)
GE (1) GEP20227382B (enExample)
IL (2) IL263272B2 (enExample)
JO (1) JOP20180121A1 (enExample)
MA (1) MA45234A (enExample)
MX (2) MX2018015757A (enExample)
MY (1) MY201852A (enExample)
NI (1) NI201800134A (enExample)
PE (1) PE20190416A1 (enExample)
PH (1) PH12018502586A1 (enExample)
SG (2) SG10202103120UA (enExample)
TN (1) TN2018000417A1 (enExample)
TW (2) TWI752964B (enExample)
UA (1) UA129793C2 (enExample)
WO (1) WO2017218371A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI752964B (zh) * 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
MX2022015959A (es) * 2020-07-02 2023-01-24 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
CA3188566A1 (en) * 2020-07-03 2022-01-06 Suzhou Alphamab Co., Ltd. Coagulation factor xi (fxi) binding protein
US20240043521A1 (en) 2021-02-09 2024-02-08 Arxx Therapeutics As Anti-S100A4 Humanized Antibodies, Uses and Methods
EP4442273A4 (en) * 2021-11-30 2025-12-24 Suzhou Alphamab Co Ltd METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOEMBOLIC DISEASES
EP4644426A1 (en) * 2022-12-30 2025-11-05 Gan & Lee Pharmaceuticals Co., Ltd. Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
US20100330103A1 (en) 2006-08-03 2010-12-30 Astrazeneca Ab Antibodies Directed to Alpha V Beta 6 And Uses Thereof
JP2011504371A (ja) 2007-11-21 2011-02-10 オレゴン ヘルス アンド サイエンス ユニバーシティー 抗第ｘｉ因子モノクローナル抗体およびその使用方法
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
US20150093395A1 (en) 2008-12-18 2015-04-02 Vanderbilt University Anti-fxi antibodies and methods of use
WO2015049280A1 (en) 2013-10-01 2015-04-09 Medimmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
TWI503328B (zh) 2003-07-15 2015-10-11 Amgen Inc 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
JP2008523842A (ja) 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP5512128B2 (ja) 2005-12-08 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー フコシルｇｍ１に対するヒトモノクローナル抗体および抗フコシルｇｍ１を使用するための方法
CN101360761B (zh) 2005-12-08 2012-09-12 米德列斯公司 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
KR20200058579A (ko) 2006-06-06 2020-05-27 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
CA2700723A1 (en) 2007-09-26 2009-04-02 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
AU2016203944A1 (en) 2007-11-21 2016-07-07 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TR201820051T4 (tr) * 2008-06-19 2019-01-21 Prothix Bv Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
PL2350304T3 (pl) 2008-10-31 2017-06-30 Janssen Biotech, Inc Związki antagonistyczne receptora podobnego do toll 3
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
JP2012521360A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
KR20110138412A (ko) 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝＦ-α 항체 및 그의 용도
PL2426148T3 (pl) 2009-04-27 2016-01-29 Kyowa Hakko Kirin Co Ltd Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
EP2949671A1 (en) 2009-10-12 2015-12-02 Pfizer Inc Cancer treatment
EP2516624B1 (en) 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Cell line 3m
JP2013519164A (ja) * 2010-02-03 2013-05-23 トリロジー アイピー ホールディングス，インコーポレイテッド モバイル通信プラン提供
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
CA2818548A1 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
AU2012236068A1 (en) 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
JP6141834B2 (ja) 2011-06-06 2017-06-07 ノヴォ ノルディスク アー／エス 治療抗体
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
HUE031089T2 (en) 2012-04-13 2017-06-28 Rottapharm Biotech Srl Anti-ADAMTS-5 antibody, derivatives and uses
SI2847228T1 (sl) 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
JP6441792B2 (ja) 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP3121273A4 (en) 2014-03-20 2017-08-30 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Antibody having infection-inhibiting activity against hepatitis c virus
EP3154584B1 (en) 2014-06-03 2021-08-04 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
MX2017001531A (es) 2014-08-08 2017-05-15 Alector Llc Anticuerpos anti-trem2 y metodos de uso de los mismos.
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
TWI752964B (zh) * 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體
PE20191319A1 (es) 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100330103A1 (en) 2006-08-03 2010-12-30 Astrazeneca Ab Antibodies Directed to Alpha V Beta 6 And Uses Thereof
US20130202621A1 (en) 2006-08-03 2013-08-08 Medimmune Limited Antibodies Directed To Alpha V Beta 6 And Uses Thereof
JP2011504371A (ja) 2007-11-21 2011-02-10 オレゴン ヘルス アンド サイエンス ユニバーシティー 抗第ｘｉ因子モノクローナル抗体およびその使用方法
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
US20150093395A1 (en) 2008-12-18 2015-04-02 Vanderbilt University Anti-fxi antibodies and methods of use
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
JP2013510164A (ja) 2009-11-04 2013-03-21 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
WO2015049280A1 (en) 2013-10-01 2015-04-09 Medimmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUN, Y. et al.，Identification of a Factor IX Binding Site on the Third Apple Domain of Activated Factor XI，THE JOURNAL OF BIOLOGICAL CHEMISTRY，1996年11月15日，Vol.271, No.46，pp.29023-29028

Also Published As

Publication number Publication date
US20170355780A1 (en) 2017-12-14
KR20190018504A (ko) 2019-02-22
CO2018013434A2 (es) 2018-12-28
EP3469002A1 (en) 2019-04-17
US20200255542A1 (en) 2020-08-13
MY201852A (en) 2024-03-20
KR102379580B1 (ko) 2022-03-29
US11512142B2 (en) 2022-11-29
AR108717A1 (es) 2018-09-19
TWI752964B (zh) 2022-01-21
US12275800B2 (en) 2025-04-15
SG10202103120UA (en) 2021-05-28
PE20190416A1 (es) 2019-03-19
AU2020210233A1 (en) 2020-08-20
IL263272B1 (en) 2025-03-01
US11485794B2 (en) 2022-11-01
JP2019521978A (ja) 2019-08-08
NZ786447A (en) 2025-06-27
CR20180583A (es) 2019-07-02
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
IL263272A (en) 2018-12-31
GEP20227382B (en) 2022-05-25
WO2017218371A1 (en) 2017-12-21
US20200317811A1 (en) 2020-10-08
BR112018075858A2 (pt) 2019-04-02
AU2020210233B2 (en) 2024-03-07
EA201892716A1 (ru) 2019-05-31
ECSP18091593A (es) 2019-01-31
US11661460B2 (en) 2023-05-30
DOP2018000284A (es) 2019-01-31
PH12018502586A1 (en) 2019-10-07
US20200270364A1 (en) 2020-08-27
US11479615B2 (en) 2022-10-25
NZ786443A (en) 2025-06-27
TWI802193B (zh) 2023-05-11
KR20210021124A (ko) 2021-02-24
SG11201810763TA (en) 2018-12-28
CN109476758A (zh) 2019-03-15
MX2018015757A (es) 2019-05-30
KR102218714B1 (ko) 2021-02-24
JP7277500B2 (ja) 2023-05-19
IL315266A (en) 2024-10-01
CA3025869C (en) 2025-10-07
JP2021101720A (ja) 2021-07-15
NI201800134A (es) 2019-03-05
MA45234A (fr) 2019-04-17
CN116425879A (zh) 2023-07-14
UA129793C2 (uk) 2025-08-06
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
AU2017286432A1 (en) 2018-12-06
AU2017286432B2 (en) 2020-09-24
CA3172367A1 (en) 2017-12-21
US20200308302A1 (en) 2020-10-01
CA3025869A1 (en) 2017-12-21
CL2018003565A1 (es) 2019-03-22
IL263272B2 (en) 2025-07-01
TW202214702A (zh) 2022-04-16
NZ786444A (en) 2025-06-27
NZ786448A (en) 2025-06-27
MX2023012740A (es) 2024-02-23
TN2018000417A1 (en) 2020-06-15
NZ786442A (en) 2025-06-27
JOP20180121A1 (ar) 2018-12-12
NZ748743A (en) 2025-06-27
TW201802120A (zh) 2018-01-16
CL2024000367A1 (es) 2024-08-23

Similar Documents

Publication Publication Date Title
US12275800B2 (en) Anti-coagulation factor XI antibodies
RU2757314C2 (ru) Антитела против фактора свертывания xi

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210326

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210611

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220204

R150 Certificate of patent or registration of utility model

Ref document number: 7022081

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250